Laurus Labs Ltd Quarterly Results

Among others, Manappuram Finance, Marico, Radico Khaitan, Redington, Welspun Corp, Laurus Labs and Sai Life Sciences also touched respective all-time highs in trade on Thursday.

Laurus Labs quoted higher for the fourth straight day, surging 15% in this period after delivering record quarterly revenue with expanded profitability and continued portfolio transformation.

G Chokkalingam, founder and head of research at Equinomics Research expects markets to reward stocks of companies where there is valuation comfort, earnings visibility rather than a broad-based rally.

The stock price of Laurus Labs hit a new high of ₹1,662.45 in intra-day deals on Monday; the stock has zoomed 176% in the past 14 months from levels of ₹601.75 on May 27, 2025.

Laurus Labs on Friday reported a 124.7% YoY surge in Q1 consolidated net profit at ₹361.99 crore, backed by 28.8% growth in total income. The stock has nearly doubled in the last one year.

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

The Nifty Midcap 50 and Smallcap 50 have gained 21 per cent and 29 per cent thus far in FY27 led by strong gains in BHEL, Laurus Labs, Prestige Estates, Aegis Logistics and Welspun Corp.

In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise in the Nifty 50.

Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, the company said.

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.